FTC Questions Apple News Over Alleged Bias Against Conservative Media 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
BERKELEY, Calif., Feb. 14, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray, Dynavax’s chief executive officer, will participate in a fireside chat at the 2018 RBC Capital Markets Global Healthcare Conference in New York City. The presentation will be webcast live and will occur on Wednesday, February 21, 2018 at 1:35 p.m. ET.
The live or replayed versions of the webcast will be available by visiting the “Investors” section of the Dynavax website at www.dynavax.com.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company's first commercial product, HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.
Contact:
David Burke
Director, Investor Relations & Corporate Communications
510.665.7269
[email protected]
